U.S. Markets open in 1 hr 17 mins

Immuno Oncology & Targeted Therapy Companies Set to Breakout

HENDERSON, NV / ACCESSWIRE / September 12, 2018 / Immuno Oncology has been getting investors revved up in 2018. Abpro and Neon announced IPOs and recently, German biotech Affimed agreed to an alliance with Roche's Genentech to discover new cancer immunotherapies with an amazing $5 billion dollar deal.

Roche – which is already an emerging player in immuno oncology with its Tecentriq (atezolizumab) PD-L1 inhibitor and a pipeline of new candidates – says it wants to use the technology across "multiple undisclosed solid and hematologic tumour targets."

Roche is not the only major player in Immuno Oncology, and you can bet their competition is working to make their own splash announcements in the coming months. With that in mind, we searched the small cap market for some of the best Immuno Oncology and targeted therapy companies that could draw interest from the larger firms.

The one we're most excited about is Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver. The company's therapy targets the liver, and the company's recent news hinted at some potential major news ahead and was a major announcement in its own right. The company recently amended its Phase 3 trial in ocular melanoma liver metastases so that it can enroll as a single-arm registration trial, reducing the number of patients required to complete enrollment. The company believes it can now complete trial enrollment by the middle of 2019. This is important because the company views its ocular melanoma trial as the fastest path to FDA drug approval.

A few CBD and Biotech stocks to consider include: Delcath Systems, Inc. (DCTH), Roche Holdings, Inc. (RHHBY), Affirmed N.V. (AFMD), Celgene Corporation. (CELG), and Iovance Biotherapeutics, Inc. (IOVA).

Delcath Systems, Inc. (DCTH)

Market Cap: $2.28M Share Price: $2.45

Delcath's investigational product – Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) – is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. DCTH has commenced a global registration FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM) and has initiated a global Phase 3 trial called The ALIGN Trial for intrahepatic cholangiocarcinoma (ICC). Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. However, in Europe, their system has been commercially available since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a wide range of cancers of the liver.

As mentioned above DCTH is in a very intriguing position for investors.

Roche Holdings, AG. (RHHBY),

Market Cap: $206B Share Price: $30.72

Mentioned above Roche is the parent company of the $5 billion dollar deal. The company is currently going through an issue in the UK with the pricing of their MS drug.

Affirmed N.V. (AFMD)

Market Cap: $299.39M Share Price: $4.79

Affirmed is the company Roche made the deal with, the stock has pulled back a bit since it's large jump on the news. It will be interesting to watch from here.

Celgene Corporation (CELG)

Market Cap: $62.8B, Share Price: $89.29

Celgene started the year off with big news taking on Juno, the company has pulled back a bit and could be eyeing other candidates soon. Maybe DCTH could draw their interest?

Iovance Biotherapeutics, Inc. (IOVA)

Market Cap: $1.18B Share Price: $12.42

The company presented H.C. Wainwright Global Investor Conference in New York City recently. Iovance offered a clinical update for its mid-stage tumor-infiltrating lymphocyte therapy, C-144-01, in patients with advanced skin cancer who have been previously treated with an anti-PD-1 and anti-CTLA-4 checkpoint inhibitor. The therapy failed to produce an objective response rate that was on par with Bristol-Myers Squibb's combination therapy (Opdivo and Yervoy) for this indication (40% vs. 50%). Chardan analyst Gbola Amusa said that out of six patients assesses, two had partial responses but their cancer later worsened. Amusa also remarked, "While preliminary data show tumor regressions, in this refractory population, the extent and durability of responses might not match those seen in melanoma."

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and three thousand dollars total by Regal Consulting. LLC, for news commentary articles for DCTH and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. We may buy or sell additional shares of ENDV in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

For Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager

Email: info@microcapspecualtors.com

Phone: 1-702-720-6310

Country: United States

Website: http://microcapspeculators.com/

SOURCE: ACR Communication LLC

https://www.accesswire.com/511804/Immuno-Oncology-Targeted-Therapy-Companies-Set-to-Breakout